RYAM's 2025 Results Confirm Earnings Decline and Cash Flow Strain Amid High Leverage

What happened

RYAM reported full-year 2025 revenue of $1.5 billion and Adjusted EBITDA of $133 million, down significantly from $222 million in 2024 due to demand disruptions and operational challenges. This performance aligns with prior guidance of $135-140 million but highlights persistent earnings pressure in a tough market environment. The company also cited negative Adjusted Free Cash Flow, exacerbating concerns about its $794 million debt load and thin liquidity, with interest coverage at just 0.05x. Despite management's ambitious turnaround plan targeting over $300 million EBITDA by 2027 through cost cuts and biomaterials, current results show limited progress in improving profitability or reducing leverage. The gap between optimistic targets and operational reality remains wide, reinforced by structural headwinds like declining acetate tow demand and competitive pressures.

Implication

The lower EBITDA and negative free cash flow underscore RYAM's inability to sustainably generate profits amid cyclical downturns, confirming DeepValue's concerns about earnings volatility. With net debt/EBITDA likely staying around 3.5x and minimal interest coverage, financial flexibility remains constrained, increasing refinancing and covenant risks. Management's cost-reduction and biomaterials initiatives must deliver rapid, tangible results to support the 2027 EBITDA target, but current performance offers little evidence of operational turnaround. External threats, such as unresolved trade disputes and input cost volatility, continue to cloud near-term recovery prospects, limiting pricing power and volume stability. Until consistent positive free cash flow and clear deleveraging emerge, investors are advised to monitor closely rather than increase exposure, as the equity remains highly speculative with narrow downside protection.

Thesis delta

The 2025 results do not shift the core thesis; they reinforce the DeepValue report's 'wait' stance by confirming earnings deterioration and cash flow challenges. However, the persistence of negative free cash flow and lack of leverage improvement could tilt the view towards a more bearish outlook if management fails to execute on cost savings or biomaterials. Overall, the thesis remains unchanged: RYAM is a leveraged turnaround with high execution risk, requiring vigilant monitoring of financial metrics and strategic milestones.